个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Fen Wang[1] * ; Xia Yuan[2] ; Jun Jia[3] ; Xiaoxia Bi[4] ; Zeqiang Zhou[5] ; Qiming Zhou[6] ; Xia Li[7] ; Changguo Luo[8] ; Minghui Deng[9] ; Liangjie Yi[10] ; Yong Li[11] ; Jianxin Lu[12] ; Wenzhi Su[13] ; Hanbin Chen[14] ; Yu Zhu[1,15] ; Shubin Wang[1,15] ;
机构： [1]Department of Oncology, Peking University Shenzhen Hospital, Guangdong, China [2]Department of Oncology,Huizhou Municipal Central Hospital, Guangdong, China [3]Department of Oncology, Dongguan People’s Hospital,Guangdong, China [4]Department of Oncology, Huizhou First People’s Hospital, Guangdong, China [5]Departmentof Oncology, Shenzhen Second People’s Hospital, Guangdong, China [6]Department of Oncology, ShenzhenNanshan People’s Hospital, Guangdong, China [7]Department of Oncology, Longgang Central Hospital of Shenzhen,Guangdong, China [8]Department of Oncology, Baoan District Traditional Chinese Medicine Hospital of Shenzhen,Guangdong, China [9]Department of Oncology, Huizhou Sixth People’s Hospital, Guangdong, China [10]Departmentof Oncology, Huizhou Traditional Chinese Medicine Hospital, Guangdong, China [11]Department of Oncology,Guangdong Hospital of Traditional Chinese Medicine, Guangdong, China [12]Department of Oncology, People’sHospital of Shanwei, Guangdong, China [13]Department of Oncology, Second People’s Hospital of Shanwei,Guangdong, China [14]Department of Oncology, Pengpai Memorial Hospital of Haifeng, Guangdong, China [15]Shenzhen Peking University-Hongkong University of Science and Technology Medical Center, Guangdong, China
出处：
DOI： 10.1038/s41598-020-62961-5
ISSN：

摘要：
Angiogenesis inhibitors are of considerable interest for treating metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of apatinib in chemotherapy-refractory mCRC. Apatinib 500 mg was administered daily to patients who had progressed after two or more lines of standard fluorouracil-based chemotherapy. Primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity. Overall, 48 patients were enrolled. ORR and DCR were 8.3% (4/48) and 68.8% (33/48), respectively. Median PFS and OS were 4.8 (95% confidence interval [CI], 3.653–5.887) and 9.1 months (95% CI, 5.155–13.045), respectively, and did not differ between subgroups stratified by previous anti-angiogenic therapies. The most prevalent grade 3–4 adverse events were hypertension (12.5%), hand-foot syndrome (HFS, 10.4%), thrombocytopenia (10.4%), and proteinuria (8.3%). Low baseline neutrophil/lymphocyte ratio (NLR, hazard ratios [HR], 0.619; P = 0.027), early carbohydrate antigen 19–9 (CA19–9) decrease (HR, 1.654; P = 0.016), and HFS (HR, 2.087; P = 0.007) were associated with improved PFS. In conclusion, apatinib monotherapy demonstrated encouraging efficacy with manageable toxicities in chemotherapy-refractory mCRC. Previous anti-angiogenic therapies did not influence outcomes. Baseline NLR, early CA19-9 decrease, and HFS could predict the efficacy of apatinib. © 2020, The Author(s).

基金：
Apatinib was provided by Jiangsu Hengrui Medicine Co., Ltd. The company offered a discount on apatinib for clinical trial participants but was not involved in the overall trial process, including trial conception and design, data acquisition and statistical analysis, writing of the manuscript, or the decision to publish this manuscript. This work was supported by the Sanming Project of Medicine in Shenzhen [grant number SZSM201612041], Natural Science Foundation of Guangdong Province [grant number 2015A030313381], Scientific Research Project of Health and Family Planning Commission of Shenzhen Municipality [grant number SZLY2018025], and Shenzhen Science and Technology Plan of International Cooperation Projects [grant number GJHZ20180420180754917].

基金编号： grant number SZSM201612041] Natural Science Foundation of Guangdong Province [grant number 2015A030313381] Scientific Research Project of Health and Family Planning Commission of Shenzhen Municipality [grant number SZLY2018025] and Shenzhen Science and Technology Plan of International Cooperation Projects [grant number GJHZ20180420180754917

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
最新[2025]版：
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
JCR分区：
出版当年[2018]版：
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者：
第一作者机构： [1]Department of Oncology, Peking University Shenzhen Hospital, Guangdong, China
通讯作者：
通讯机构： [1]Department of Oncology, Peking University Shenzhen Hospital, Guangdong, China [15]Shenzhen Peking University-Hongkong University of Science and Technology Medical Center, Guangdong, China
推荐引用方式(GB/T 7714)：
Fen Wang,Xia Yuan,Jun Jia,et al.Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study[J].SCIENTIFIC REPORTS.2020,10(1):doi:10.1038/s41598-020-62961-5.
APA：
Fen Wang,Xia Yuan,Jun Jia,Xiaoxia Bi,Zeqiang Zhou...&Shubin Wang.(2020).Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study.SCIENTIFIC REPORTS,10,(1)
MLA：
Fen Wang,et al."Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study".SCIENTIFIC REPORTS 10..1(2020)

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号